The National Organization for Rare Disorders (NORD), a nonprofit organization dedicated to supporting those with rare diseases, has launched…
Joana Carvalho, PhD
Editorial Associate Director of Resource Pages
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.
Education
- PhD, Biomedical Sciences, specialty of Molecular and Cellular Biology
- MSc, Evolutionary and Developmental Biology
- BSc, Biology, speciality Evolutionary and Developmental Biology
Certifications
- ICH Good Clinical Practice E6 (R2)
Published Works
- Non-canonical Wnt signaling regulates junctional mechanocoupling during angiogenic collective cell migration. eLife · 2019
- YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. eLife · 2018
- Endothelial cell dynamics in vascular remodelling. Clinical Hemorheology and Microcirculation · 2016
Professional Accomplishments
- Awarded 2 Erasmus scholarships, several research fellowships, a scholarship conference award, and an honorable mention.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Joana Carvalho, PhD
Argenx has filed an application to the U.S. Food and Drug Administration (FDA) requesting the approval of…
Quality of life tends to be poorer in people with myasthenia gravis (MG) who develop the disease later in…
Older patients with myasthenia gravis (MG) who receive treatment with intravenous immunoglobulin (IVIG) may be at a higher…
Johnson & Johnson will acquire Momenta Pharmaceuticals, which has been developing nipocalimab (M281) for the treatment of myasthenia…
High levels of kappa free light chain — a protein that makes up a portion of immunoglobulins (antibodies)…
Soliris (eculizumab) may be a promising treatment option for patients with refractory myasthenia gravis (MG) associated with…
Immunovant is preparing to launch a Phase 3 trial of its investigational candidate IMVT-1401 in patients with myasthenia gravis…
Defects in mitophagy — the process that degrades defective mitochondria, the cell compartments responsible for producing energy —…
Rituximab seems to be more effective in newly-diagnosed patients with generalized myasthenia gravis (gMG), compared to people at…